Program
fezolinetant
Also written as “Fezolinetant”, “fezolinetant - test formulation” and “fezolinetant - reference formulation”.
Its studies are mostly in Hot Flashes · Prostatic Neoplasms · Renal Insufficiency, led by Astellas Pharma.
Furthest: phase 3, since Jun 27, 201921 company-led studies, 3 open or runningNext primary completion: Apr 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Astellas Pharma | 213 open or running | phase 3since Jun 27, 2019 | Jun 15, 2017 | Apr 30, 2027phase 1 · NCT07783282 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 5 studies since Jun 15, 2017.
- Jan 16, 2020Phase 3 study in Hot FlashesNCT04234204 · 302 enrolled · China, Korea, Republic of, Taiwan
- Feb 18, 2020Phase 1 study in Healthy VolunteersNCT04277624 · 22 enrolled · United States
- Jun 26, 2020Phase 3 study in Hot FlashesNCT04451226 · 150 enrolled · China
- Jul 15, 20202 phase 1 studiesNCT04476849, NCT04482270
- Nov 20, 2020Phase 1 study in Healthy SubjectsNCT04641260 · 16 enrolled · United States
- Mar 9, 2021Phase 1 study in Healthy VolunteersNCT04793204 · 16 enrolled · China
- Sep 1, 2021Phase 2 study in Hot FlashesNCT05034042 · 147 enrolled · Japan
- Sep 1, 2021Phase 3 study in Vasomotor SymptomsNCT05033886 · 453 enrolled · Belgium, Canada, Czechia and more
- Jun 6, 2022Phase 2 study in Hot FlashesNCT05419908 · 87 enrolled · Belgium
- Jan 4, 20242 phase 3 studies in Hot FlashesNCT06206421, NCT06206408
- May 29, 2024Phase 3 study in Hot FlashesNCT06440967 · 982 enrolled · Canada, Czechia, Denmark and more
- Feb 3, 2025Phase 2 study in Hot FlashesNCT06812754 · 150 enrolled · China
- Aug 20, 2026Phase 1 study in Prostatic NeoplasmsNCT07783282 · 56 planned · Bulgaria
- Sep 15, 2026Phase 3 study in Hot FlashesNCT07829653 · 100 planned · India
Ahead
- Apr 30, 2027Primary completion: phase 1 study in Prostatic NeoplasmsNCT07783282
- Mar 31, 2028Primary completion: phase 3 study in Hot FlashesNCT07829653
TargetBeta
TACR3 →read by rule
“An orally bioavailable, neurokinin/tachykinin 3 receptor (NK1-receptor; NK3R; NK-3R) antagonist, that can be used to treat vasomotor symptoms (VMS) in menopausal woman”NCIt, by rule
“Neurokinin 3 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| GS1-144rule | Changchun GeneScience Pharmaceutical | phase 2 | 6 |
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07829653Hot Flashes · India | 3 | Recruiting | Mar 31, 2028 | 100 |
| NCT07783282Prostatic Neoplasms · Bulgaria | 1 | Recruiting | Apr 30, 2027 | 56 |
| NCT06812754Hot Flashes · China | 2 | Completed | Feb 11, 2026 | 150 |
| NCT06440967Hot Flashes · Canada, Czechia, Denmark and more | 3 | Active, not recruiting | Jun 25, 2026 | 982 |
| NCT06206421Hot Flashes · Japan | 3 | Completed | Mar 19, 2026 | 277 |
| NCT06206408Hot Flashes · Japan | 3 | Completed | Oct 22, 2025 | 410 |
| NCT05419908Hot Flashes · Belgium | 2 | Completed | Sep 21, 2016 | 87 |
| NCT05034042Hot Flashes · Japan | 2 | Completed | Nov 11, 2022 | 147 |
| NCT05033886Vasomotor Symptoms · Belgium, Canada, Czechia and more | 3 | Completed | Mar 27, 2023 | 453 |
| NCT04793204Healthy Volunteers · China | 1 | Completed | May 21, 2021 | 16 |
| NCT04641260Healthy Subjects · United States | 1 | Completed | Feb 12, 2021 | 16 |
| NCT04482270Hepatic Impairment · United States | 1 | Completed | Mar 22, 2021 | 26 |
| NCT04476849Renal Insufficiency · United States | 1 | Completed | Mar 6, 2022 | 27 |
| NCT04451226Hot Flashes · China | 3 | Completed | Jun 13, 2022 | 150 |
| NCT04277624Healthy Volunteers · United States | 1 | Completed | Feb 21, 2021 | 22 |
| NCT04234204Hot Flashes · China, Korea, Republic of, Taiwan | 3 | Completed | Apr 20, 2022 | 302 |
| NCT04003389Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Jan 4, 2022 | 1,831 |
| NCT04003155Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Oct 29, 2020 | 527 |
| NCT04003142Hot Flashes · United States, Canada, Czechia and more | 3 | Completed | Jul 30, 2020 | 501 |
| NCT03436849Healthy Subjects · Japan | 1 | Completed | May 23, 2018 | 44 |
| NCT03192176Hot Flashes · United States | 2 | Completed | Sep 19, 2018 | 356 |
How it is read
Names in the registry
- “Fezolinetant”, 12 entries
- “fezolinetant”, 7 entries
- “fezolinetant - test formulation”, 1 entry
- “fezolinetant - reference formulation”, 1 entry
- “ESN364”, 1 entry
Conditions, from the studies’ own filings
- Hot Flashes, 13 studies
- Prostatic Neoplasms, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.